TheStreet upgraded shares of Hologic (NASDAQ:HOLX) from a c+ rating to a b rating in a research report sent to investors on Wednesday morning, TheStreetRatingsTable reports.
Other research analysts have also recently issued research reports about the company. Zacks Investment Research raised Hologic from a hold rating to a buy rating and set a $46.00 target price on the stock in a research note on Wednesday, May 29th. Piper Jaffray Companies increased their target price on Hologic from $49.00 to $59.00 and gave the company an overweight rating in a research note on Thursday. ValuEngine cut Hologic from a buy rating to a hold rating in a research note on Thursday. Needham & Company LLC reissued a buy rating and issued a $57.00 target price (up previously from $52.00) on shares of Hologic in a research note on Thursday. Finally, BTIG Research reissued a buy rating and issued a $52.00 target price on shares of Hologic in a research note on Thursday. One research analyst has rated the stock with a sell rating, eight have given a hold rating and five have given a buy rating to the company. Hologic currently has a consensus rating of Hold and a consensus price target of $46.77.
Shares of NASDAQ:HOLX traded down $0.58 during trading on Wednesday, hitting $50.25. 1,379,905 shares of the company were exchanged, compared to its average volume of 1,700,057. The firm has a market cap of $13.80 billion, a P/E ratio of 22.53, a PEG ratio of 2.38 and a beta of 0.72. The firm’s 50 day moving average is $48.43. Hologic has a 52-week low of $37.47 and a 52-week high of $52.19. The company has a current ratio of 1.45, a quick ratio of 1.02 and a debt-to-equity ratio of 1.31.
In other news, insider Peter J. Valenti III sold 4,545 shares of the firm’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $44.07, for a total transaction of $200,298.15. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.90% of the stock is currently owned by company insiders.
Large investors have recently made changes to their positions in the company. Fox Run Management L.L.C. purchased a new stake in shares of Hologic during the second quarter worth about $576,000. Contravisory Investment Management Inc. purchased a new stake in shares of Hologic during the first quarter worth about $373,000. Stephens Investment Management Group LLC boosted its holdings in shares of Hologic by 0.6% during the first quarter. Stephens Investment Management Group LLC now owns 693,183 shares of the medical equipment provider’s stock worth $33,550,000 after purchasing an additional 4,176 shares during the period. Toronto Dominion Bank boosted its holdings in shares of Hologic by 17.5% during the first quarter. Toronto Dominion Bank now owns 192,929 shares of the medical equipment provider’s stock worth $9,336,000 after purchasing an additional 28,706 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of Hologic by 5.3% during the fourth quarter. Geode Capital Management LLC now owns 3,805,329 shares of the medical equipment provider’s stock worth $156,146,000 after purchasing an additional 190,788 shares during the period. 96.45% of the stock is currently owned by hedge funds and other institutional investors.
Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Featured Story: Trading based on a resistance level
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.